dc.contributor.author | Allen, CE | |
dc.contributor.author | Welford, AJ | |
dc.contributor.author | Matthews, TP | |
dc.contributor.author | Caldwell, JJ | |
dc.contributor.author | Collins, I | |
dc.date.accessioned | 2020-08-17T15:22:26Z | |
dc.date.issued | 2014-01-01 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330797000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier.citation | MEDCHEMCOMM, 2014, 5 (2), pp. 180 - 185 (6) | |
dc.identifier.issn | 2040-2503 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3976 | |
dc.identifier.eissn | 2040-2511 | |
dc.identifier.doi | 10.1039/c3md00308f | |
dc.description.abstract | <p>The selectivity patterns of kinase hinge-binding fragments can be retained during fragment growing, suggesting a new way to control poly-pharmacology.</p> | |
dc.format.extent | 180 - 185 (6) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ROYAL SOC CHEMISTRY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Biochemistry & Molecular Biology | |
dc.subject | Chemistry, Medicinal | |
dc.subject | Pharmacology & Pharmacy | |
dc.subject | INHIBITORS | |
dc.subject | DISCOVERY | |
dc.subject | CANCER | |
dc.subject | IDENTIFICATION | |
dc.subject | EVOLUTION | |
dc.subject | TYROSINE | |
dc.title | Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1039/c3md00308f | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2014-01-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | MEDCHEMCOMM | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.publication-status | Published | |
pubs.volume | 5 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 2 | |
dc.contributor.icrauthor | Matthews, Thomas | |
dc.contributor.icrauthor | Caldwell, John | |
dc.contributor.icrauthor | Collins, Ian | |